PLANEGG / MUNICH, GERMANY / ACCESSWIRE / December 14, 2017 / MorphoSys AG (FRA: MOR; Prime Standard Segment, TecDAX; XETRA: MOR; OTC PINK: MPSYY) will present at the following conferences:
J.P. Morgan Annual Healthcare Conference
- Date: January 10, 2018, 12:00 pm PST (09:00 pm CET, 8:00 pm GMT)
- Venue: San Francisco, CA, USA
- Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG
Jens Holstein, Chief Financial Officer of MorphoSys AG
Dr. Malte Peters, Chief Development Officer of MorphoSys AG
Anke Linnartz, Head of Corporate Communications & IR
Kepler Cheuvreux German Corporate Conference
- Date: January 15, 2018, 2:45 pm CET (8:45 am EST, 1:45 pm GMT)
- Venue: Frankfurt, Germany
- Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG
Anke Linnartz, Head of Corporate Communications & IR
LEERINK Partners 7th Annual Global Healthcare Conference
- Date: February 14-15, 2018
- Venue: New York, USA
- Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG
Anke Linnartz, Head of Corporate Communications & IR
Oddo Seydler German Conference
- Date: February 21-22, 2018
- Venue: Frankfurt, Germany
- Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG
Anke Linnartz, Head of Corporate Communications & IR
PDF versions of the presentations will be provided at www.morphosys.com. The link to the webcasts will be filed under www.morphosys.com/conference-calls.
About MorphoSys:
MorphoSys's mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. Innovative technologies and smart development strategies are central to our approach. Success is created by our people, who focus on excellence in all they do, collaborate closely across disciplines and are driven by a desire to make the medicines of tomorrow a reality. Success benefits all of our stakeholders.
Based on its proprietary technology platforms, particularly in the field of fully human therapeutic antibodies, MorphoSys, together with its partners, has built a pipeline of more than 100 programs in R&D, around a quarter of which are currently in clinical development.
In its proprietary development segment, MorphoSys, alone or with partners, is developing new therapeutic candidates, mainly focusing on cancer and inflammation. In its partnered discovery segment, MorphoSys uses its technologies to discover new drug candidates for pharmaceutical partners and participates in the programs' further development success, through success-based payments and royalties. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®, 100 billion high potentials®, Slonomics®, Lanthio Pharma®, and LanthioPep® are registered trademarks of the MorphoSys Group.
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Anke Linnartz
Head of Corporate Communications & IR
Jochen Orlowski
Associate Director Corporate Communications & IR
Alexandra Goller
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
investors@morphosys.com
SOURCE: MorphoSys Group
